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MaBACKGROUND Guidelines recommend initiating primary prevention for atherosclerotic cardiovascular disease (ASCVD)
with statins based on absolute ASCVD risk assessment. Recently, alternative trial-based and hybrid approaches were
suggested for statin treatment eligibility.
OBJECTIVES This study compared these approaches in a direct head-to-head fashion in a contemporary population.
METHODS The study used the CGPS (Copenhagen General Population Study) with 37,892 subjects aged 40 to 75 years
recruited in 2003 to 2008, all free of ASCVD, diabetes, and statin use at baseline.
RESULTS Among the population studied, 42% were eligible for statin therapy according to the 2013 American College
of Cardiology/American Heart Association (ACC/AHA) risk assessment and cholesterol treatment guidelines approach,
versus 56% with the trial-based approach and 21% with the hybrid approach. Among these statin-eligible subjects, the
ASCVD event rate per 1,000 person-years was 9.8, 6.8, and 11.2, respectively. The ACC/AHA-recommended absolute risk
score was well calibrated around the 7.5% 10-year ASCVD risk treatment threshold and discriminated better than the
trial-based or hybrid approaches. Compared with the ACC/AHA risk-based approach, the net reclassiﬁcation index for
eligibility for statin therapy among 40- to 75-year-old subjects from the CGPS was –0.21 for the trial-based approach and
–0.13 for the hybrid approach.
CONCLUSIONS The clinical performance of the ACC/AHA risk-based approach for primary prevention of ASCVD with
statins was superior to the trial-based and hybrid approaches. Our results indicate that the ACC/AHA guidelines will
prevent more ASCVD events than the trial-based and hybrid approaches, while treating fewer people compared with the
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2700(Class I recommendation) (1). However, as re-
cognized by the developers of the PCEs (2) and
highlighted by others (8–12), the PCE-based
risk calculator overestimates ASCVD risk sys-
tematically in many modern cohorts, which
could lead to statin overuse.SEE PAGE 2710Given the large number of randomized
controlled trials (RCTs) of statin therapy now
available, the appropriateness of continued
use of absolute risk prediction to guide statinallocation has been questioned (8,13). Indeed, the
clinical performance of the traditional risk-based
approach recommended in current guidelines (1–5)
has never been formally tested. In addition, no RCT
of statin therapy has ever enrolled patients based on
predicted 10-year ASCVD risk, and the clinical utility
of absolute risk assessment has never been evaluated
in a primary prevention setting. Alternatively, a so-
called “trial-based” approach has been proposed in
which statins should be offered to patient pop-
ulations for whom RCTs support statin efﬁcacy, dis-
regarding individual risk assessment and absolute
risk (8,13). More recently, a combined risk- and trial-
based strategy for the allocation of statin therapy in
primary prevention was proposed, the so-called
hybrid approach (14).
To the best of our knowledge, the clinical perfor-
mance of these strategies for statin allocation in pri-
mary prevention of ASCVD has never been compared.
We therefore performed a head-to-head comparison
of the ACC/AHA risk-based approach (1,2) versus 2
recently proposed alternative approaches (the trial-
based approach [8,13] and a hybrid approach [14]) in
a large, contemporary European cohort, the CGPS
(Copenhagen General Population Study).
METHODS
The CGPS is an ongoing prospective cohort study of
the Danish general population (15–18). Enrollment
began in 2003, and participants are randomly selected
through the Danish Civil Registration system to
reﬂect the Danish general population ages 20 to
100 years. All participants are white and of Danish
descent. For the present study, participants enrolled
between 2003 and 2008 were included. After exclu-
sion of patients with diabetes, ASCVD, or statin use
or those with missing information at baseline,
46,092 were available for analysis. As in the ACC/AHA
guidelines, the age range was limited to 40 to 75 years
(N ¼ 37,892). The study was conducted in accordance
with the Declaration of Helsinki and approved by
Herlev and Gentofte Hospital, Copenhagen UniversityHospital, and a Danish ethical committee. Written
informed consent was obtained from all participants.
Baseline examination, ASCVD endpoints, and char-
acteristics of individuals in the CGPS cohort are
described in the Online Appendix.
The 2013 ACC/AHA risk assessment and cholesterol
treatment guidelines recommend moderate- to high-
intensity statin therapy for primary prevention in
subjects aged 40 to 75 years without clinical ASCVD or
diabetes but with low-density lipoprotein (LDL)
cholesterol levels 70 to 189 mg/dl and an estimated
10-year ASCVD risk $7.5% (1). Adults aged >20 years
with LDL cholesterol levels $190 mg/dl should be
treated with high-intensity statin therapy, regardless
of risk. These are the only 2 Class I statin recom-
mendations in the guideline for subjects free of
ASCVD and diabetes (Figure 1), whereas those with
ASCVD and/or diabetes likewise should be prescribed
statins. Identiﬁcation and validation of ASCVD events
for the present study (described in the Online
Appendix) are identical to the approach used previ-
ously (18).
As an alternative to risk-based statin allocation,
Ridker et al. (8,13) proposed a trial-based approach
guided by the enrollment criteria used in the
following 6 large primary prevention RCTs of statin
therapy: WOSCOPS (West of Scotland Coronary Pre-
vention Study) (19), AFCAPS/TexCAPS (Air Force/
Texas Coronary Atherosclerosis Prevention Study)
(20), ASCOT-LLA (Anglo-Scandinavian Cardiac Out-
comes Trial–Lipid Lowering Arm) (21), MEGA (Man-
agement of Elevated Cholesterol in the Primary
Prevention Group of Adult Japanese) (22), JUPITER
(Justiﬁcation for the Use of Statins in Prevention: an
Intervention Trial Evaluating Rosuvastatin) (23), and
CARDS (Collaborative Atorvastatin Diabetes Study)
(24). Because CARDS enrolled only patients with
diabetes who, according to guidelines, should be
offered statins, we disregarded CARDS in our com-
parison of the 2 strategies and focused on participants
without diabetes. Characteristics of the 5 RCTs pro-
posed to guide the trial-based allocation of statins in
the primary prevention of ASCVD are shown in
Figure 1 and Online Table 1.
More recently, Riker et al. (14) proposed a hybrid
approach in which eligibility for primary prevention
with statins requires both a PCE 10-year ASCVD
risk $7.5% (ACC/AHA Class I recommendation) and
trial-based evidence of beneﬁt. In contrast to the
trial-based approach, the ASCOT trial is not used to
provide trial-based evidence in the hybrid approach
(14), and the trial-based inclusion criteria are not
strictly met but based on a compromise and general-
ization beyond the age and sex limits set by some of
FIGURE 1 Eligibility Criteria for Statin Therapy
Risk-based approach
ACC/AHA Guidelines
Eligibility for statin therapy: Eligibility for statin therapy:
Age: 40-75 years
10-year ASCVD risk ≥7.5%
or
LDL-C ≥190
Initiation of statin therapy in people free of ASCVD and diabetes
Trial-based approach
Ridker et al.
Men 45-64 years
TC ≥252 + LDL-C ≥155
TC 180-264 + LDL-C 130-190
(WOSCOPS)
or
Men 45-73 and women 55-73 years
+HDL-C ≤45 (men)/≤47 (women)
(AFCAPS/TexCAPS)
(AFCAPS/TexCAPS)
or
Men and women 40-79 years
Men and women 40-70 years
Untreated SBP ≥160 or DBP ≥100 mm Hg
or treated SBP ≥140 or DBP ≥90 mm Hg
+ TC ≤251 + ≥3 risk factors besides HTN
(ASCOT-LLA)
or
TC 220-270
(MEGA)
or
Men ≥50 and women ≥60 years
LDL-C <130 + hsCRP ≥2.0 mg/L
(JUPITER)
(JUPITER)
Hybrid approach
Ridker et al.
Eligibility for statin therapy:
Age: 45-79 years
10-year ASCVD risk ≥7.5%
(ACC/AHA risk-based approach)
Plus:
LDL-C ≥160
(WOSCOPS, MEGA)
or
or
LDL-C 130-160 + HDL-C ≤45
LDL-C <130 + hsCRP ≥2
The criteria vary greatly for initiating statin therapy in subjects free of atherosclerotic cardiovascular disease (ASCVD) and diabetes as deﬁned
by the American College of Cardiology/American Heart Association (ACC/AHA) risk-based approach, the trial-based approach, and the hybrid
approach. AFCAPS/TexCAPS ¼ Air Force/Texas Coronary Atherosclerosis Prevention Study; ASCOT-LLA ¼ Anglo-Scandinavian Cardiac
Outcomes Trial–Lipid Lowering Arm; DBP ¼ diastolic blood pressure; HDL-C ¼ high-density lipoprotein cholesterol; hsCRP ¼ high-sensitivity
C-reactive protein; HTN ¼ hypertension; JUPITER ¼ Justiﬁcation for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosu-
vastatin; LDL-C ¼ low-density lipoprotein cholesterol; MEGA ¼ Management of Elevated Cholesterol in the Primary Prevention Group of Adult
Japanese; SBP ¼ systolic blood pressure; TC ¼ total cholesterol; WOSCOPS ¼ West of Scotland Coronary Prevention Study.
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2701the statin trials. The compromise applies to both
sexes aged 45 to 79 years (Figure 1).
STATISTICAL ANALYSIS. The number and percent-
age of participants eligible for statin therapy were
calculated based on the 3 approaches described
earlier. We also created area-proportional Venn dia-
grams to assess agreement and disagreement in statin
recommendations according to the 3 approaches.
Using the aforementioned criteria for statin therapy,
we then calculated the observed event rate per 1,000
person-years among statin-eligible participants.
We assessed calibration of the PCEs ASCVD risk
equations. Because the CGPS has not yet completed
10 years of follow-up, 5-year predicted and observed
ASCVD event rates were calculated when assessing
calibration of PCEs, as previously performed (25).
Calibration within the risk groups was assessed by
using the predicted-to-observed event ratio. The
observed number of ASCVD events at 5 years was
adjusted for variable follow-up time by using the
Kaplan-Meier estimate. Subsequently, the area underthe receiver-operating characteristic curve was
calculated for discrimination between cases (those
who did develop ASCVD during follow-up) and non-
cases for the 3 different approaches to statin therapy.
The clinical usefulness and impact on ASCVD pre-
vention of a guideline-deﬁned treatment threshold
depend on its ability to correctly assign treatment
(statins) to subjects who develop ASCVD in the future
(sensitivity). However, this method should be
balanced with the risk of treating those who do not
need treatment (speciﬁcity). We therefore calculated
the sensitivity, speciﬁcity, and the binary net reclas-
siﬁcation index (NRI) when comparing the ACC/AHA
risk-based approach with the trial-based and hybrid
approaches. The binary NRI (to treat or not to treat) is
the sum of D-sensitivity and D-speciﬁcity, and the
theoretical range is –2 to 2.
Additional information on statistics is provided in
the Online Appendix. Analyses were performed by
using Stata/SE version 13.1 (StataCorp LP, College
Station, Texas).
TABLE 1 Baseline Characteristics
All Men Women
Participants 37,892 16,398 21,494
Age, yrs 56 (48-64) 56 (48–64) 55 (48–64)
SBP, mm Hg 139 (125–152) 140 (130–155) 135 (122–150)
DBP, mm Hg 84 (77–90) 85 (80–93) 81 (75–90)
Plasma cholesterol, mmol/l
Total cholesterol 5.7 (5.1–6.4) 5.7 (5.1–6.4) 5.8 (5.1–6.5)
HDL cholesterol 1.6 (1.3–2.0) 1.4 (1.1–1.7) 1.8 (1.5–2.1)
LDL cholesterol 3.3 (2.8–4.0) 3.4 (2.8–4.0) 3.3 (2.7–3.9)
% current smokers 23 24 22
10-year ASCVD risk, %* 5.3 (1.9–12.3) 9.4 (4.2–17.4) 3.2 (1.1–7.8)
ASCVD events 834 467 367
Myocardial infarction 323 210 113
Values are n or median (interquartile range) unless otherwise indicated. *Based on pooled cohort
equations.
ASCVD ¼ atherosclerotic cardiovascular disease; DBP ¼ diastolic blood pressure; HDL ¼ high-
density lipoprotein; LDL ¼ low-density lipoprotein; SBP ¼ systolic blood pressure.
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Baseline characteristics of the study population are
shown in Table 1. All 37,892 subjects (57% women)
were free of ASCVD, diabetes, and statin use at
baseline. During 182,641 person-years of follow-up,FIGURE 2 Statin Eligibility
0 20 4
Fraction Eligible for Statins Am
and Diabetes fro
All
N = 37 892
Men
N = 16 398
Women
N = 21 494
Hybrid approach
Hybrid ap
Hybrid approach
ACC/AHA a
ACC/AHA
criteria
LDL-C ≥190 mg/dL
10-year ASCVD risk ≥7.5%
Using the ACC/AHA, trial-based, and hybrid approaches, the fraction of
diabetes, or statin use selected from CGPS (Copenhagen General Populat
eligible subjects were selected consecutively in chronological order from
WOSCOPS criteria (1995), and additional subjects were then selected ac
bars ¼ combined WOSCOPS and MEGA. Abbreviations as in Figure 1.834 developed ASCVD, of which 323 were myocar-
dial infarctions.
STATIN ELIGIBILITY. More subjects were eligible for
statin therapy with the trial-based approach compared
with the ACC/AHA risk-based approach (56% vs. 42%;
p < 0.0001) (Figure 2, Central Illustration). This ﬁnding
was true for women (49% vs. 29%; p < 0.0001) and for
men (67% vs. 60%; p< 0.0001). By contrast, the hybrid
approach substantially reduced the proportion of
subjects eligible for statin therapy compared with the
ACC/AHA approach (21% vs. 42%; p<0.0001).With the
hybrid approach, 30% of men and 14% of women
qualiﬁed for statin therapy.
The 3 different approaches to statin allocation
produced overlap in statin eligibility (Figure 3). By
deﬁnition, those qualifying for statin therapy with
the hybrid approach also did so with the ACC/AHA
risk-based approach. However, 20% of participants in
CGPS were eligible for statins with the ACC/AHA risk-
based approach but not the hybrid approach. In
contrast, substantially different groups of subjects
were eligible for statin therapy according to the trial-
based approach. Thus, for 41% of participants, there
was a disagreement regarding statin recommenda-
tions between the trial-based approach and the0 60 80
ong Individuals without ASCVD
m the CGPS (%)
ACC/AHA approach
Trial-based approach
ACC/AHA approach
Trial-based approach
proach
Trial-based approach
pproach
Primary
prevention
trials
WOSCOPS
AFCAPS/TexCAPS
ASCOT-LLA
MEGA
JUPITER
statin-eligible subjects aged 40 to 75 years without clinical ASCVD,
ion Study) was calculated. For the trial-based and hybrid approaches,
left to right; that is, subjects were ﬁrst selected according to
cording to AFCAPS/TexCAPS criteria (1998), and so on. Checkered
CENTRAL ILLUSTRATION Primary Prevention: Approaches to Guide
Statin Therapy
ASCVD event rate per 1,000 person-year
10                                         7                                        11         
Reference                         -0.21                                  -0.13         
Net reclassification index
21%
Trial-based 
 Approach
42%
  Hybrid
Approach
 ACC/AHA
Risk-based 
 Approach
Eligible for statin therapy in primary prevention
56%
37,892 individuals (40-75 years old) recruited in 2003-2008,
      all free of ASCVD, diabetes, and statin use at baseline
Copenhagen General Population Study
Mortensen, M.B. et al. J Am Coll Cardiol. 2015; 66(24):2699–709.
With the trial-based approach, more people were eligible for statin therapy; of those
selected for treatment, there was a lower atherosclerotic cardiovascular disease (ASCVD)
event rate compared with the American College of Cardiology/American Heart Association
(ACC/AHA) risk-based approach or the hybrid approach. As assessed by using the net
reclassiﬁcation index, the clinical performance of the ACC/AHA approach was superior to
the other approaches and prevented more ASCVD events than the trial-based approach by
treating fewer people.
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2703ACC/AHA risk-based approach. Among those who
qualiﬁed for statin treatment according to the trial-
based approach, 68% of women and 32% of men had
a 10-year ASCVD risk <7.5%, disqualifying them un-
der the ACC/AHA approach.
Of those eligible for statin therapy, the ASCVD
event rate per 1,000 person-years was 9.8 (95% con-
ﬁdence interval [CI]: 9.1 to 10.6) with the ACC/AHA
approach, 6.8 (95% CI: 6.3 to 7.4) with the trial-based
approach, and 11.2 (95% CI: 10.1 to 12.5) with the
hybrid approach (Table 2). Accordingly, the predicted
10-year ASCVD risk in those eligible for statin therapy
was highest for the hybrid approach, lower for the
ACC/AHA approach, and lowest for the trial-based
approach (Table 3). Characteristics of participants
eligible for primary prevention with statins using the
3 different approaches are presented in Table 3.
CALIBRATION, DISCRIMINATION, AND CLINICAL
PERFORMANCE. The ACC/AHA PCE-based risk score
overestimated 10-year ASCVD risk in subjects with
relatively high risk (>10% 10-year ASCVD risk), but it
was reasonably well calibrated around the 7.5%
treatment threshold, with predicted/observed ratios
ranging from 1.1 to 1.2 (Figure 4). The ACC/AHA Class I
recommendations for statin therapy discriminated
substantially better between cases (those who did
develop ASCVD during follow-up) and noncases than
the enrollment criteria used in statin RCTs or ac-
cording to the treatment criteria deﬁned by the
hybrid approach (Table 4): the area under the
receiver-operating characteristic curve was 0.676
for the ACC/AHA approach, 0.572 for the trial-based
approach, and 0.613 for the hybrid approach
(p < 0.0001 for all comparisons).
Compared with the risk-based approach recom-
mended by the ACC/AHA guidelines, the 2-category
NRI for eligibility for statin therapy (yes or no)
among 40- to 75-year-old subjects from CGPS was
–0.21 for the trial-based approach and –0.13 for the
hybrid approach (Table 4). These values were similar
for men and women separately.
Both sensitivity and speciﬁcity were higher in men
with the ACC/AHA risk-based approach compared
with the trial-based approach (Table 4). In women,
only speciﬁcity was higher. The hybrid approach had
a lower sensitivity but a higher speciﬁcity than the
ACC/AHA risk-based approach. The shared pro-
portions of subjects correctly identiﬁed as going to
develop ASCVD (sensitivity) using statin eligibility
criteria as deﬁned by the 3 approaches are shown in
Online Figure 1; their baseline characteristics are
shown in Online Tables 2 to 4 and Figure 5. Those not
eligible for statin with any approach had high lip-
oprotein(a) levels.DISCUSSION
In a contemporary European cohort, the clinical per-
formance of the ACC/AHA risk-based approach for
ASCVD primary prevention with statins was superior
to the trial-based and hybrid approaches (Central
Illustration). Our results indicate that the ACC/AHA
guidelines will prevent more ASCVD events than the
trial-based and hybrid approaches; compared with
the trial-based approach, it will prevent more ASCVD
events by treating fewer people.
Based on enrollment criteria used in 5 primary
prevention RCTs, more subjects were eligible for statin
therapy with the trial-based approach recommended
by Ridker et al. (8,13) than with the risk-based
approach recommended by the ACC/AHA guidelines.
Even more people might have been eligible for
TABLE 2 Observed A
Observed ASCVD event
1,000 person-ye
ACC/AHA approach
Trial-based approach
Hybrid approach
Observed no. of ASCVD
ACC/AHA approach
Trial-based approach
Hybrid approach
5-year KM-adjusted
observed events
ACC/AHA approach
Trial-based approach
Hybrid approach
Statin-eligible subjects we
ACC/AHA ¼ American
KM ¼ Kaplan-Meier; other
FIGURE 3 Overlap in Statin Eligibility
Overlap of 40- to 75-year-old individuals eligible for statin therapy
All
N = 37,892
Men
N = 16,398
Women
N = 21,494
Not eligible: 31% Not eligible: 21% Not eligible: 38%
28%
12%
16% 5%
8%
20%
18%
28% 3%
10%
33%
8%
8%
7%
6%Tr
ial
-b
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A 
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Area-proportional Venn diagrams demonstrate overlap in statin eligibility with the ACC/AHA risk-based approach (light green), the trial-based
approach (red), and the hybrid approach (peach). The percentages indicate the fraction of all subjects in CGPS aged 40 to 75 years who were
eligible for statin therapy. Abbreviations as in Figures 1 and 2.
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2704statin therapy with the trial-based approach by
applying wider enrollment criteria; that is, by
covering >5 of the 18 primary prevention RCTs
included in a recent Cochrane review (26). Thus,
allocation of statins based on a trial-based approach
endorsing the principle of “What works and in
whom?” signiﬁcantly increases the number of
subjects recommended for statin therapy compared
with the ACC/AHA guideline. This ﬁnding is not un-
expected because the ACC/AHA guidelines aim to offer
statins to those who will likely beneﬁt the most,SCVD Event Rate in Statin-Eligible Subjects
All Men Women
rate per
ars (95% CI)
9.8 (9.1–10.6) 10.3 (9.3–11.3) 9.0 (7.9–10.3)
6.8 (6.3–7.4) 8.0 (7.2–8.3) 5.6 (4.9–6.3)
11.2 (10.1–12.5) 11.7 (10.2–13.3) 10.5 (8.8–12.5)
events
639 411 228
586 355 231
357 231 126
(95% CI)
788 (723–855) 509 (459–565) 278 (242–319)
733 (671–801) 435 (389–486) 295 (256–340)
444 (397–495) 287 (250–326) 156 (130–188)
re selected as shown in Figures 1 and 2.
College of Cardiology/American Heart Association; CI ¼ conﬁdence intervals;
abbreviation as in Table 1.whereas enrollment criteria in RCTs are decided
by using many other criteria, including regulatory
approval and commercial interests. By contrast, we
observed that substantially fewer subjects were
eligible for statin therapy with the hybrid approach
(14). This approach, among those eligible for statin
therapy according to the ACC/AHA guidelines, only
selects those with evidence from trials of a clinical
beneﬁt.
RCT EVIDENCE USE. The evidence behind the 3
strategies originates exclusively from RCTs of statin
therapy, but the evidence is used differently. In the
risk-based approach (1,2), results from RCTs are used
to show that the relative risk reduction by statin
therapy is dose dependent and similar in all tested
subgroups (except for patients with congestive heart
failure or undergoing hemodialysis), regardless of sex
and enrollment criteria. Thus, in primary prevention,
global risk assessment and absolute ASCVD risk can
be used to balance expected beneﬁt of treatment
against risk of harm. By contrast, global risk assess-
ment is irrelevant in the trial-based approach in
which RCTs are used to identify those subjects in
whom efﬁcacy of statin therapy has been documented
(8,13).
In a risk-based strategy, the risk score used must be
well calibrated to the target population to treat sub-
jects as intended. In the CGPS, the ACC/AHA-
recommended PCEs were reasonably well calibrated
around the 7.5% treatment threshold. However, cali-
bration depends on the target population and may
change over the course of time, requiring regular
TABLE 3 Baseline Characteristics: Statin Therapy Eligibility Stratiﬁed According to Approach
Men Women
ACC/AHA Eligible Trial-Based Eligible Hybrid Eligible ACC/AHA Eligible Trial-Based Eligible Hybrid Eligible
Participants 9,754 10,902 4,870 6,228 10,419 2,963
Age, yrs 62 (56–68) 57 (50–64) 61 (56–67) 67 (62–71) 59 (52–65) 67 (63–71)
SBP, mm Hg 147 (135–160) 145 (132–160) 148 (135–160) 150 (136–165) 141 (128–160) 152 (140–167)
DBP, mm Hg 88 (80–95) 88 (80–96) 88 (80–96) 85 (80–92) 85 (78–92) 86 (80–94)
Plasma cholesterol, mmol/l
Total cholesterol 5.9 (5.3–6.6) 6.0 (5.5–6.5) 6.2 (5.4–7.0) 6.4 (5.7–7.2) 6.0 (5.7–6.4) 6.7 (5.7–7.4)
HDL cholesterol 1.4 (1.1–1.7) 1.4 (1.1–1.7) 1.2 (1.0–1.5) 1.7 (1.4–2.1) 1.8 (1.5–2.2) 1.6 (1.2–2.0)
LDL cholesterol 3.6 (3.0–4.2) 3.7 (3.1–4.2) 4.1 (3.2–4.6) 3.9 (3.2–4.7) 3.5 (3.0–3.9) 4.3 (3.2–4.8)
% current smokers 34 26 37 33 22 38
10-year ASCVD risk, % 15.5 (10.8–22.8) 11.5 (6.0–19.1) 16.9 (11.9–24.4) 12.0 (8.8–17.5) 4.5 (2.0–9.1) 13.3 (9.8–18.7)
Values are n or median (interquartile range) unless otherwise indicated.
Abbreviations as in Tables 1 and 2.
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2705assessment and recalibration. This goal is chal-
lenging, exempliﬁed by miscalibration of PCEs in
certain modern U.S. cohorts (8,9,11) (although these
cohorts may not all be representative of the entire
U.S. population) and by suboptimal guidance to
ethnic groups other than non-Hispanic white and
African-American subjects in the 2013 ACC/AHA
guidelines (1,2). However, it is reasonable to suggest
that the present calibration results based on the CGPS
may resemble what could be expected for large partsFIGURE 4 Observed ASCVD Events Versus Predicted Risk
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The pooled cohort equations (PCE) in the ACC/AHA guidelines overestim
the 7.5% 10-year ASCVD risk threshold for statin therapy. Because CGPS
on 5-year Kaplan-Meier adjusted observed events and predicted events
calibration (i.e., predicted events ¼ observed events). Error bars ¼ 95%
P/O ¼ predicted/observed.of the U.S. population of white European descent:
Denmark, as with the United States, has experienced
a major drop in ASCVD rates over the last decades that
coincides with major decreases in smoking rates and
increases in statin use.
The trial-based strategy does not rely on a risk
score, but the generalizability and durability of re-
sults obtained in randomized statin trials enrolling
selected populations up to decades ago may also be
questioned with respect to applicability to theEvents in 5 years
-year predicted
ASCVD risk
Kaplan-Meier
adjusted observed, % Predicted, % P/O ratio
<5%
5% to <7.5%
7.5% to <10%
≥10%
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ated risk in subjects at highest risk for ASCVD but were well calibrated around
has not yet completed 10 years of follow-up, the calibration assessment is based
previously calculated according to the 5-year PCE (25). Orange line ¼ perfect
conﬁdence intervals. ASCVD ¼ atherosclerotic cardiovascular disease;
FIGURE 5 Baseline
Statin eligibilit
Statin eligibility by ACC/
Statin eligibility by ACC/
but not hybrid
Statin eligibility by Trial-
but not ACC/AHA
Not eligible for statin
by any approach
Individual baseline c
alone and with comb
TABLE 4 Clinical Performance: ASCVD Event Identiﬁcation
NRI DSensitivity (%) DSpeciﬁcity (%) Sensitivity (%) Speciﬁcity (%) AUC
All
ACC/AHA Ref Ref Ref 77 59 0.676 (Ref)
Trial-based –0.21 (p < 0.0001) –7 (p ¼ 0.002) –13 (p < 0.0001) 70 45 0.572 (p < 0.0001)
Hybrid –0.13 (p < 0.0001) –34 (p < 0.0001) 21 (p < 0.0001) 42 80 0.613 (p < 0.0001)
Men
ACC/AHA Ref Ref Ref 88 41 0.647 (Ref)
Trial-based –0.21 (p < 0.0001) –14 (p < 0.0001) –8 (p < 0.0001) 76 33 0.549 (p < 0.0001)
Hybrid –0.12 (p ¼ 0.001) –42 (p < 0.0001) 30 (p < 0.0001) 49 71 0.602 (p < 0.0001)
Women
ACC/AHA Ref Ref Ref 62 72 0.669 (Ref)
Trial-based –0.19 (p < 0.0001) 1 (p ¼ 0.83) –20 (p < 0.0001) 63 52 0.574 (p < 0.0001)
Hybrid –0.13 (p < 0.0001) –28 (p < 0.001) 15 (p < 0.0001) 34 87 0.605 (p < 0.0001)
AUC ¼ area under the curve; NRI ¼ net reclassiﬁcation index (Dsensitivity þ Dspeciﬁcity); other abbreviations as in Table 2.
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2706entire general population (27). Indeed, clinical
endpoints differed (19–23) and >10 exclusion criteria
(23,28,29) were common in such trials. One trial
ended up enrolling only 4% of those invited to be
screened (19); another randomized only 6% of
those who attended pre-trial cholesterol screeningCharacteristics of Individuals Who Developed an ASCVD Event Stratiﬁed
0.0 0.5 1.0 0.0 0.5 1.0 0.0
0.0 0.5 1.0 0.0 0.5 1.0 0.0
0.0 0.5 1.0 0.0 0.5 1.0 0.0
Proportion of CGPS Eligible for Statin
Proportion with Cholesterol > 5 mmol/L Proportion with LDL-C > 3 mmol/L
Proportion with Age > 60 years
Pro
Proportion with SBP > 140 mm HgProportion with Triglycerides > 2 mmol/L
Age
Total cholesterol LDL cholesterol
Systolic blood pressureTriglycerides
y
AHA
AHA
based
P
haracteristics of participants who developed an ASCVD event were stratiﬁed
ined approaches. CRP ¼ C-reactive protein; Lp(a) ¼ lipoprotein(a); remnant-(20). It is thus uncertain how well these study
participants, who were enrolled in trials to assess
efﬁcacy and safety in selected populations, repre-
sent individuals in real-world clinical practice (27).
Finally, many high-risk subjects were excluded
from these RCTs and will, in principle, remainAccording to Statin Eligibility Approach
0.5 1.0 0.0 0.5 1.0
0.5 1.0 0.0 0.5 1.0
0.5 1.0 0.0 0.5 1.0
portion with HDL-C < 1 mmol/L Proportion with Remnant-C > 1 mmol/L
Proportion Who SmokesMale, %
Sex Smoking
HDL cholesterol Remnant cholesterol
C-reactive protein Lipoprotein(a)
roportion with CRP > 2 mg/L Proportion with LP(a) > 50 mg/dL
according to statin eligibility with the ACC/AHA risk-based approach
C ¼ remnant cholesterol; other abbreviations as in Figures 1 and 2.
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2707ineligible for statin therapy with the trial-based
approach, including those with familial hypercho-
lesterolemia (30).
TO TREAT OR NOT TO TREAT WITH STATINS. The
ACC/AHA guidelines recommend the new 7.5% risk
threshold based on risk/beneﬁt considerations (1,2).
A commensurate risk threshold was more recently
recommended by the National Institute for Health
and Care Excellence in the United Kingdom based
on cost-effectiveness considerations (4,5). Impor-
tantly, such a cutoff can be modiﬁed by those who
disagree with the underlying assumptions (31), and
it can be changed over time as, for example, ASCVD
rates and statin availability changes and as new
cholesterol-lowering drugs become available. By
contrast, in the trial-based approach, and partly in
the hybrid approach, the “cutoff” is given a priori
by the enrollment criteria in the undertaken
RCTs, producing poorer discrimination to statin allo-
cation between cases and noncases than the
ACC/AHA risk-based approach. Importantly, using
the trial-based approach instead of the risk-based
approach was detrimental to all clinical performance
parameters. Noteworthy, because age dominates
among risk predictors, the risk-based approach inevi-
tably will favor statin treatment of older people,
disregarding younger people with a high lifetime
ASCVD risk (32,33). However, the ACC/AHA guidelines
recommend statin therapy initiation only within the
context of a clinician–patient discussion to determine
beneﬁts, harms, and patient preferences, allowing
for more lenient initiation of preventive measures
in older subjects with favorable risk factors.
Unless speciﬁc contraindications exist, all who
have similar absolute risk are treated equally in the
risk-based approach, regardless of sex and ethnicity
(1,2). The number-needed-to-treat is constant for a
given absolute risk, and women will, in general,
qualify for statin therapy approximately 10 years later
in life than men because their absolute risk is lower
than in men of the same age. In the trial-based
approach, women at lower absolute risk may qualify
equally for statin therapy as high-risk men of similar
age if “positive” RCT data are available. Thus, the
number-needed-to-treat will be higher in low-risk
women than in high-risk men (34), and the same
will apply to all low-risk subjects who were enrolled
in RCTs.
In CGPS, a larger proportion of participants, espe-
cially women, would qualify for statin therapy with
the trial-based approach compared with the ACC/AHA
risk-based approach, meaning that statin treatment
should be initiated at a much earlier age in women
at low risk. This ﬁnding may be surprising,considering that data from WHS (Women’s Health
Study) were used to express concern about potential
overuse of statins based on the new ACC/AHA
guidelines, and the trial-based approach was recom-
mended to avoid overtreatment (8). Recent data (9)
indicate that only 12% of women in WHS would
qualify for ACC/AHA risk-based statin therapy (PCE
risk $7.5%). By contrast, with a mean cholesterol
level of 212 mg/dl and a median C-reactive protein
level $2.0 mg/l in WHS (35), substantially more
women would qualify for statin therapy based on the
enrollment criteria used in AFCAPS/TexCAPS, MEGA,
and JUPITER, as illustrated in the present study based
on CGPS.
STUDY LIMITATIONS. A potential limitation of the
application of trial-based and hybrid approaches to
statin allocation in our study is the limited ability to
consider all the exclusion criteria used in the RCTs
of statins. However, potential exclusion criteria were
not mentioned in the alternative proposals (8,13,14),
and trial exclusion criteria are often ignored in
routine clinical practices (27). Another limitation is
that we only studied white subjects, and our results
therefore do not necessarily apply to other ethnic-
ities. Because follow-up in CGPS was <10 years, we
assessed PCE calibration by using a 5-year model
(25), assuming that the correlation of 5- to 10-year
ASCVD events in CGPS is similar to that observed
in the PCE cohorts. Finally, although use of pre-
ventive medications was limited during follow-up
(18), preferential prescription of such medications
to those at highest risk might have contributed to
the observed overestimation of risk in subjects with
PCE >10%.
Our study possesses several strengths. Our results
originate from a contemporary, population-based,
large cohort with complete follow-up. In addition,
predicted outcomes were appropriately identiﬁed
and adjudicated, which is essential to assess calibra-
tion of a risk score. Finally, and just as importantly,
the ACC/AHA PCE-based 10-year ASCVD risk score in
the CGPS cohort was reasonably well calibrated
around the 7.5% Class I recommendation for statin
therapy in the primary prevention of ASCVD.
CONCLUSIONS
In CGPS, the ACC/AHA risk-based approach to pri-
mary prevention of ASCVD with statins was superior
to the trial-based approach assessed by discrimina-
tion, sensitivity, speciﬁcity, and binary NRI, indi-
cating that more ASCVD events will be prevented by
treating fewer subjects. The recently proposed hybrid
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: The decision to initiate
preventive statin therapy should be based on ASCVD
risk assessment rather than on criteria used to include
patients in RCTs.
TRANSLATIONAL OUTLOOK: Future research
should be directed toward developing more accurate
cardiovascular risk prediction tools.
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2708approach substantially decreased the number of
subjects eligible for statin therapy in the general
population, but the balance between sensitivity and
speciﬁcity still favored the ACC/AHA risk-based
approach.
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